相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis
Edward Fox et al.
MULTIPLE SCLEROSIS JOURNAL (2021)
Role of B Cells in Multiple Sclerosis and Related Disorders
Giancarlo Comi et al.
ANNALS OF NEUROLOGY (2021)
Targeting B Cells to Modify MS, NMOSD, and MOGAD Part 1
Jonas Graf et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2021)
Ofatumumab versus Teriflunomide in Multiple Sclerosis
Stephen L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Infusion-related reactions to rituximab: frequency, mechanisms and predictors
Franciane Paul et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2019)
Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis
Ralph H. B. Benedict et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
S. L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
X. Montalban et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis
Ralph H. B. Benedict et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Rituximab in multiple sclerosis A retrospective observational study on safety and efficacy
Jonatan Salzer et al.
NEUROLOGY (2016)
Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion
M. Le Garff-Tavernier et al.
LEUKEMIA (2014)
Magnetic resonance imaging outcomes from a phase III trial of teriflunomide
Jerry S. Wolinsky et al.
MULTIPLE SCLEROSIS JOURNAL (2013)
Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria
Chris H. Polman et al.
ANNALS OF NEUROLOGY (2011)
Analysis of CD16(+)CD56(dim) NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies
M. Le Garff-Tavernier et al.
LEUKEMIA (2011)
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
Paul O'Connor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcγRIIIA/CD16
Christophe de Romeuf et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
分享论文
